ASX Mkt. Sensitive<p>Orthocell ( <a href="https://mastodon-grafa.social/tags/OCC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OCC</span></a> ) has released " Trading Halt " on Thu 03 Apr at 09:06 AEST <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <br><a href="https://grafa.com/asset/orthocell-ltd-177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/orthocell-ltd-</span><span class="invisible">177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx</span></a></p>
Recent searches
No recent searches
Search options
Not available on writing.exchange.
writing.exchange is one of the many independent Mastodon servers you can use to participate in the fediverse.
A small, intentional community for poets, authors, and every kind of writer.
Administered by:
Server stats:
336active users
writing.exchange: About · Profiles directory · Privacy policy
Mastodon: About · Get the app · Keyboard shortcuts · View source code · v4.3.7
#clinicaltrials
6 posts · 3 participants · 0 posts today
ASX Mkt. Sensitive<p>Race Oncology ( <a href="https://mastodon-grafa.social/tags/RAC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>RAC</span></a> ) has released " RC220 Phase 1 Trial Opens for Patient Enrolment " on Thu 03 Apr at 08:57 AEST <a href="https://mastodon-grafa.social/tags/UnitedStates" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStates</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/race-oncology-ltd-3890-rac.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=rac.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/race-oncology-</span><span class="invisible">ltd-3890-rac.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=rac.asx</span></a></p>
ASX Mkt. Sensitive<p>Bioxyne ( <a href="https://mastodon-grafa.social/tags/BXN" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BXN</span></a> ) has released " BXN Signs Exclusive $7m Manufacturing and Supply Agreement " on Thu 03 Apr at 08:32 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <br><a href="https://grafa.com/asset/bioxyne-ltd-6076-bxn.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=bxn.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/bioxyne-ltd-60</span><span class="invisible">76-bxn.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=bxn.asx</span></a></p>
ASX Mkt. Sensitive<p>Opthea ( <a href="https://mastodon-grafa.social/tags/OPT" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OPT</span></a> ) has released " Opthea Announces Decision to Discontinue Wet AMD Trials " on Mon 31 Mar at 12:41 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <br><a href="https://grafa.com/asset/opthea-ltd-3521-opt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=opt.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/opthea-ltd-352</span><span class="invisible">1-opt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=opt.asx</span></a></p>
ASX Mkt. Sensitive<p>Nyrada ( <a href="https://mastodon-grafa.social/tags/NYR" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NYR</span></a> ) has released " First Cohort Dosed in Nyradas Phase I Clinical Trial " on Mon 31 Mar at 09:52 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/nyrada-inc-3430-nyr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nyr.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/nyrada-inc-343</span><span class="invisible">0-nyr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=nyr.asx</span></a></p>
ASX Mkt. Sensitive<p>Archer Materials ( <a href="https://mastodon-grafa.social/tags/AXE" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>AXE</span></a> ) has released " AXE partners with Hylid Diagnostics for Biochip development " on Mon 31 Mar at 09:11 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <a href="https://mastodon-grafa.social/tags/rise" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>rise</span></a> <br><a href="https://grafa.com/asset/archer-exploration-ltd-5699-axe.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=axe.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/archer-explora</span><span class="invisible">tion-ltd-5699-axe.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=axe.asx</span></a></p>
Technology Tales<p>The future of statistical programming recruitment lies in adaptability and expertise beyond SAS. As clinical trials become more complex, the demand for skills in automation, real-world evidence, and AI integration is rising. Companies must update their hiring strategies to ensure compliance and efficiency, focusing on programmers with the right hybrid skills. <a href="https://mstdn.social/tags/StatisticalProgramming" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>StatisticalProgramming</span></a> <a href="https://mstdn.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mstdn.social/tags/AI" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>AI</span></a> <a href="https://mstdn.social/tags/Recruitment" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Recruitment</span></a> <a href="https://www.warmanobrien.com/resources/blog/top-5-skills-defining-statistical-programming-recruitment/" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="ellipsis">warmanobrien.com/resources/blo</span><span class="invisible">g/top-5-skills-defining-statistical-programming-recruitment/</span></a></p>
ASX Mkt. Sensitive<p>Race Oncology ( <a href="https://mastodon-grafa.social/tags/RAC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>RAC</span></a> ) has released " Race Initiates First AU Site for Phase 1 Solid Tumour Trial " on Thu 27 Mar at 15:53 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <br><a href="https://grafa.com/asset/race-oncology-ltd-3890-rac.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=rac.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/race-oncology-</span><span class="invisible">ltd-3890-rac.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=rac.asx</span></a></p>
ASX Mkt. Sensitive<p>Actinogen Medical ( <a href="https://mastodon-grafa.social/tags/ACW" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ACW</span></a> ) has released " ACW conducts Type C meeting with FDA regarding depression " on Thu 27 Mar at 11:58 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/actinogen-medical-ltd-5264-acw.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=acw.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/actinogen-medi</span><span class="invisible">cal-ltd-5264-acw.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=acw.asx</span></a></p>
ASX Mkt. Sensitive<p>Alterity Therapeutics ( <a href="https://mastodon-grafa.social/tags/ATH" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ATH</span></a> ) has released " Alterity Completes Last Patient Visit in Open-Label Trial " on Thu 27 Mar at 10:41 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <br><a href="https://grafa.com/asset/alterity-therapeutics-ltd-641-ath.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=ath.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/alterity-thera</span><span class="invisible">peutics-ltd-641-ath.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=ath.asx</span></a></p>
IQWiG<p>What to do if <a href="https://wisskomm.social/tags/PubMed" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>PubMed</span></a> goes down the drain </p><p>The news from the US is unsettling, not least for medical information specialists. Siw Waffenschmidt, Head of our Department of Information Management, asks <span class="h-card" translate="no"><a href="https://mastodon.online/@hildabast" class="u-url mention" rel="nofollow noopener noreferrer" target="_blank">@<span>hildabast</span></a></span>, author of the blog 'Absolutely Maybe' and former NIH employee, for an assessment of the situation regarding PubMed and <a href="https://wisskomm.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a>.gov. How can all of us prepare for possible PubMed downtimes or deficiencies?</p><p><a href="https://youtu.be/fn2paCE6Zco?si=atNcEhzfP3Ptbuuk" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">youtu.be/fn2paCE6Zco?si=atNcEh</span><span class="invisible">zfP3Ptbuuk</span></a></p>
ASX Mkt. Sensitive<p>Orthocell ( <a href="https://mastodon-grafa.social/tags/OCC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OCC</span></a> ) has released " First Sales of Striate in Germany, Austria & Swiss Region " on Wed 26 Mar at 09:02 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <br><a href="https://grafa.com/asset/orthocell-ltd-177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/orthocell-ltd-</span><span class="invisible">177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx</span></a></p>
US News in English<p>Kezar Life Sciences reports positive results for zetomipzomib and 2024 fina... - published 25 Mar 2025 <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <br><a href="https://grafa.com/news/health-kezar-life-sciences-reports-positive-results-for-zetomipzomib-and-2024-financials-405779?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=405779" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-kezar-li</span><span class="invisible">fe-sciences-reports-positive-results-for-zetomipzomib-and-2024-financials-405779?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=405779</span></a></p>
ASX Mkt. Sensitive<p>EBR Systems ( <a href="https://mastodon-grafa.social/tags/EBR" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>EBR</span></a> ) has released " 2024 Activity Report and Form 10-K submission " on Tue 25 Mar at 08:48 AEST <a href="https://mastodon-grafa.social/tags/NYSE" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NYSE</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <br><a href="https://grafa.com/asset/ebr-systems-inc-cdr-6751-ebr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=ebr.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/ebr-systems-in</span><span class="invisible">c-cdr-6751-ebr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=ebr.asx</span></a></p>
ASX Mkt. Sensitive<p>Memphasys ( <a href="https://mastodon-grafa.social/tags/MEM" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MEM</span></a> ) has released " Trading Halt " on Thu 20 Mar at 08:52 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <br><a href="https://grafa.com/asset/memphasys-ltd-8352-mem.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=mem.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/memphasys-ltd-</span><span class="invisible">8352-mem.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=mem.asx</span></a></p>
ASX Mkt. Sensitive<p>Opthea ( <a href="https://mastodon-grafa.social/tags/OPT" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OPT</span></a> ) has released " Voluntary suspension " on Wed 19 Mar at 09:36 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <br><a href="https://grafa.com/asset/opthea-ltd-3521-opt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=opt.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/opthea-ltd-352</span><span class="invisible">1-opt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=opt.asx</span></a></p>
ASX Mkt. Sensitive<p>EMvision Medical Devices ( <a href="https://mastodon-grafa.social/tags/EMV" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>EMV</span></a> ) has released " First Responder Scanner in Successful Aeromedical Testing " on Wed 19 Mar at 08:17 AEST <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/emvision-medical-devices-ltd-1711-emv.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=emv.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/emvision-medic</span><span class="invisible">al-devices-ltd-1711-emv.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=emv.asx</span></a></p>
US News in English<p>Zentalis Pharmaceuticals announces promising results for azenosertib in ova... - published 17 Mar 2025 <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/gas" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>gas</span></a> <a href="https://mastodon-grafa.social/tags/Pharmaceuticals" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Pharmaceuticals</span></a> <a href="https://mastodon-grafa.social/tags/Grafa" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Grafa</span></a> <br><a href="https://grafa.com/news/health-zentalis-pharmaceuticals-announces-promising-results-for-azenosertib-in-ovarian-cancer-399260?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=399260" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-zentalis</span><span class="invisible">-pharmaceuticals-announces-promising-results-for-azenosertib-in-ovarian-cancer-399260?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=399260</span></a></p>
ASX Mkt. Sensitive<p>Bluechiip ( <a href="https://mastodon-grafa.social/tags/BCT" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BCT</span></a> ) has released " Responsible Entity Appointment/Resignation " on Mon 17 Mar at 17:05 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/ASIC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASIC</span></a> <br><a href="https://grafa.com/asset/bluechiip-ltd-783-bct.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=bct.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/bluechiip-ltd-</span><span class="invisible">783-bct.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=bct.asx</span></a></p>
ASX Mkt. Sensitive<p>Opthea ( <a href="https://mastodon-grafa.social/tags/OPT" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OPT</span></a> ) has released " Trading Halt " on Mon 17 Mar at 08:41 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <br><a href="https://grafa.com/asset/opthea-ltd-3521-opt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=opt.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/opthea-ltd-352</span><span class="invisible">1-opt.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=opt.asx</span></a></p>
ExploreLive feeds
Mastodon is the best way to keep up with what's happening.
Follow anyone across the fediverse and see it all in chronological order. No algorithms, ads, or clickbait in sight.
LoginDrag & drop to upload